Citations

Showing 10 of 108152 citations.

Feasibility of a Patient-Reported Outcomes Quality of Life Instrument to Improve Care in Underserved, Ethnic Minority Cancer Patients
Khera, Nandita , Komenaka, Ian K. , Ramos, Gilbert , Fruth, Briant, Arslan, Waqas, Northfelt, Donald W. , Warsame, Rahma , Sloan, Jeff A. , Griffin, Joan M.

Mayo Clinic

No container title available | July 22, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.11758/v1 Get It

Abstract Background A better understanding of social determinants of health and psychosocial and economic sequelae of cancer for an ethnoculturally diverse population is needed. A Patient-Reported Outcomes Quality of Life (PROQOL) instrument has been developed to capture less commonly discussed patient concerns. We sought to adapt this instrument and pilot it in underserved, ethnic minority cancer patients at Maricopa Integrated Health System (MIHS) in Phoenix, AZ. Methods Two focus groups (FG) were conducted to understand patient perspectives of an adapted Spanish version of PROQOL. A revised version based on FG data was then piloted among patients on active cancer treatment. Patients also completed a Linear Analog Scale Assessment (from 1-10) for quality of life (QOL) and its domains. Results All participants in both FG (11/12 female) were Hispanic, with a median age of 53 years. Participants agreed that the domains covered in the PROQOL represented the most important psychosocial needs in their cancer continuum. No difficulty in understanding the individual domains or questions for delving deeper into each domain was noted. Median age of 34 pilot study participants (74% female, 79% Hispanic) was 48 years. 28/34 completed the Spanish version. The most common concerns were ‘Money’ (32%) and ‘Cancer Diagnosis, Treatment and Survivorship’ (32%). Median overall QOL was 8 (range 3-10). Conclusions PROQOL is feasible for systematic capture of patient concerns in underserved, ethnic minority cancer patients. A better understanding of these concerns can help design interventions to improve psychosocial outcomes for the vulnerable groups and decrease disparities in care delivery.
Use of Acupuncture in Overweight/Obese Women with Polycystic Ovary Syndrome
Yang, Juan , Chon, Tony Y. , Bauer, Brent A.

Mayo Clinic

Medical Acupuncture | July 22, 2019 | Volume: 31 | Issue: 5 | Pages: 267-268

10.1089/acu.2019.1375 | PMID 31624524 Get It

Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine
Compton, Carolyn C. , Robb, James A., Anderson, Matthew W. , Berry, Anna B. , Birdsong, George , Bloom, Kenneth J., Branton, Philip A. , Crothers, Jessica W. , Cushman‐Vokoun, Allison M. , Hicks, David G., Khoury, Joseph D. , Laser, Jordan , Marshall, Carrie B. , Misialek, Michael J., Natale, Kristen E. , Nowak, Jan A. , Olson, Damon R. , Pfeifer, John D. , Schade, Andrew E., Vance, Gail H. , Walk, Eric , Yohe, Sophia , Birdsong, George G, Nowak, Jan Anthony, Olson, Damon, Schade, Andrew, Walk, Eric E, Yohe, Sophia Louise, Berry, Anna , Olson, Damon R

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 22, 2019 | Volume: 143 | Issue: 11 | Pages: 1346-1363

10.5858/arpa.2019-0009-sa | PMID 31329478 Get It

Biospecimens acquired during routine medical practice are the primary sources of molecular information about patients and their diseases that underlies precision medicine and translational research. In cancer care, molecular analysis of biospecimens is especially common because it often determines treatment choices and may be used to monitor therapy in real time. However, patient specimens are collected, handled, and processed according to routine clinical procedures during which they are subjected to factors that may alter their molecular quality and composition. Such artefactual alteration may skew data from molecular analyses, render analysis data uninterpretable, or even preclude analysis altogether if the integrity of a specimen is severely compromised. As a result, patient care and safety may be affected, and medical research dependent on patient samples may be compromised. Despite these issues, there is currently no requirement to control or record preanalytical variables in clinical practice with the single exception of breast cancer tissue handled according to the guideline jointly developed by the American Society of Clinical Oncology and College of American Pathologists (CAP) and enforced through the CAP Laboratory Accreditation Program. Recognizing the importance of molecular data derived from patient specimens, the CAP Personalized Healthcare Committee established the Preanalytics for Precision Medicine Project Team to develop a basic set of evidence-based recommendations for key preanalytics for tissue and blood specimens. If used for biospecimens from patients, these preanalytical recommendations would ensure the fitness of those specimens for molecular analysis and help to assure the quality and reliability of the analysis data.
World Brain Day 2019; migraine – the painful truth
Wijeratne, Tissa , Dodick, DW, Grisold, Wolfgang , Carroll, William M. , Wijeratne, T

Mayo Clinic

European Journal of Neurology | July 22, 2019 | Volume: 26 | Issue: 11 | Pages: No page available

10.1111/ene.14045 | PMID 31329327 Get It

Association Between Stress Testing–Induced Myocardial Ischemia and Clinical Events in Patients With Multivessel Coronary Artery Disease
Garzillo, Cibele Larrosa , Hueb, Whady , Rezende, Paulo Cury , Favarato, Desidério , Filho, Roberto Kalil , Gersh, Bernard J. , Lima, Eduardo Gomes , Ramires, José Antônio Franchini

Mayo Clinic

JAMA Internal Medicine | July 22, 2019 | Volume: 179 | Issue: 10 | Pages: 1345

10.1001/jamainternmed.2019.2227 | PMID 31329221 Get It

Faculty Opinions recommendation of Comparison of the Opn-CreER and Ck19-CreER Drivers in Bile Ducts of Normal and Injured Mouse Livers.
Huebert, Robert C.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | July 22, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735611695.793562565 Get It

ICAR: endoscopic skull‐base surgery
Zanation, Adam M., Gardner, Paul A. , Schwartz, Theodore H. , Eloy, Jean Anderson , Adappa, Nithin D. , Bettag, Martin, Casiano, Roy R. , Cavallo, Luigi Maria , Ebert, Charles S. , Evans, James J., Fernandez‐Miranda, Juan C. , Folbe, Adam J. , Froelich, Sébastien , Gentili, Fred, Harvey, Richard J. , Hwang, Peter H. , Jane, John A. , Kennedy, David W. , Knosp, Engelbert, Lee, John Y. K. , Lund, Valerie J. , Prevedello, Daniel M. , Schlosser, Rodney J. , Sindwani, Raj , Solares, C. Arturo , Tabaee, Abtin, Teo, Charles , Thirumala, Parthasarathy D. , Thorp, Brian D. , Vellutini, Eduardo de Arnaldo Silva , Witterick, Ian , Woodworth, Bradford A. , Wormald, Peter‐John , Mukherjee, Debraj , Wang, Eric W , Eloy, Jean Anderson , Lal, Devyani , Schlosser, Rodney J , Mukherjee, Debraj , Harvey, Richard J , Hwang, Peter H , Prevedello, Daniel M , Adappa, Nithin D. , Bleier, Benjamin S. , Cappabianca, Paolo , Carrau, Ricardo L. , El‐Sayed, Ivan H. , Kelly, Daniel F. , Lal, Devyani , Liu, James K. , Snyderman, Carl H

Mayo Clinic

International Forum of Allergy & Rhinology | July 22, 2019 | Volume: 9 | Issue: S3 | Pages: No page available

10.1002/alr.22326 | PMID 31329374 Get It

Background Endoscopic skull‐base surgery (ESBS) is employed in the management of diverse skull‐base pathologies. Paralleling the increased utilization of ESBS, the literature in this field has expanded rapidly. However, the rarity of these diseases, the inherent challenges of surgical studies, and the continued learning curve in ESBS have resulted in significant variability in the quality of the literature. To consolidate and critically appraise the available literature, experts in skull‐base surgery have produced the International Consensus Statement on Endoscopic Skull‐Base Surgery (ICAR:ESBS). Methods Using previously described methodology, topics spanning the breadth of ESBS were identified and assigned a literature review, evidence‐based review or evidence‐based review with recommendations format. Subsequently, each topic was written and then reviewed by skull‐base surgeons in both neurosurgery and otolaryngology. Following this iterative review process, the ICAR:ESBS document was synthesized and reviewed by all authors for consensus. Results The ICAR:ESBS document addresses the role of ESBS in primary cerebrospinal fluid (CSF) rhinorrhea, intradural tumors, benign skull‐base and orbital pathology, sinonasal malignancies, and clival lesions. Additionally, specific challenges in ESBS including endoscopic reconstruction and complication management were evaluated. Conclusion A critical review of the literature in ESBS demonstrates at least the equivalency of ESBS with alternative approaches in pathologies such as CSF rhinorrhea and pituitary adenoma as well as improved reconstructive techniques in reducing CSF leaks. Evidence‐based recommendations are limited in other pathologies and these significant knowledge gaps call upon the skull‐base community to embrace these opportunities and collaboratively address these shortcomings.
Smartphone-Based Analysis of Urine Reagent Strips Is Inaccurate for Assessing Underhydration
Adams, J.D. , Capitán-Jiménez, Catalina , Burchfield, Jenna M., Jansen, Lisa T. , Kavouras, Stavros A.

Mayo Clinic

Telemedicine and e-Health | July 22, 2019 | Volume: 26 | Issue: 5 | Pages: 683-686

10.1089/tmj.2019.0101 | PMID 31329074 Get It

Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals
Iniesta, Raquel , Campbell, Desmond , Venturini, Cristina , Faconti, Luca , Irvin, Marguerite R. , Johnson, Julie A. , Arnett, Donna K. , Weale, Michael E. , Munroe, Patricia B. , Cruickshank, Kennedy, Lewis, Cathryn M. , Chowienczyk, Phil , Turner, Stephen T. , Arnett, Donna K , Munroe, Patricia B , Singh, Sonal , Cooper‐DeHoff, Rhonda M. , Warren, Helen R. , Padmanabhan, Sandosh , Lewis, Cathryn M

Mayo Clinic

Hypertension | July 22, 2019 | Volume: 74 | Issue: 3 | Pages: 614-622

10.1161/hypertensionaha.118.12177 | PMID 31327267 Get It

Selection of antihypertensive treatment according to self-defined ethnicity is recommended by some guidelines but might be better guided by individual genotype rather than ethnicity or race. We compared the extent to which variation in blood pressure response across different ethnicities may be explained by genetic factors: genetically defined ancestry and gene variants at loci known to be associated with blood pressure. We analyzed data from 5 trials in which genotyping had been performed (n=4696) and in which treatment responses to β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blocker, thiazide or thiazide-like diuretic and calcium channel blocker were available. Genetically defined ancestry for proportion of African ancestry was computed using the 1000 genomes population database as a reference. Differences in response to the thiazide diuretic hydrochlorothiazide, the β-blockers atenolol and metoprolol, the angiotensin-converting enzyme inhibitor lisinopril, and the angiotensin receptor blocker candesartan were more closely associated to genetically defined ancestry than self-defined ethnicity in admixed subjects. A relatively small number of gene variants related to loci associated with drug-signaling pathways ( KCNK3, SULT1C3, AMH, PDE3A, PLCE1, PRKAG2 ) with large effect size (−3.5 to +3.5 mm Hg difference in response per allele) and differing allele frequencies in black versus white individuals explained a large proportion of the difference in response to candesartan and hydrochlorothiazide between these groups. These findings suggest that a genomic precision medicine approach can be used to individualize antihypertensive treatment within and across populations without recourse to surrogates of genetic structure such as self-defined ethnicity.
Factors Associated With the Decision-Making on Endovascular Thrombectomy for the Management of Acute Ischemic Stroke
Saposnik, Gustavo , Menon, Bijoy K. , Kashani, Nima , Wilson, Alexis , Baxter, Blaise, Turjman, Francis , Fischer, Urs , Mitchell, Peter , Sylaja, Pillai N., Cherian, Mathew , Kim, Byung Moon , Heo, Ji Hoe , Podlasek, Anna , Foss, M , Hill, Michael D. , Hill, Michael D , Fischer, Urs , Yoshimura, Shinichi , Campbell, Bruce , Rabinstein, Alejandro A. , Ospel, Johanna M. , Almekhlafi, Mohammed , Demchuk, Andrew M. , Goyal, Mayank

Mayo Clinic

Stroke | July 22, 2019 | Volume: 50 | Issue: 9 | Pages: 2441-2447

10.1161/strokeaha.119.025631 | PMID 31327314 Get It

Background and Purpose— Little is known about the real-life factors that clinicians use in selection of patients that would receive endovascular treatment (EVT) in the real world. We sought to determine patient, practitioner, and health system factors associated with therapeutic decisions around endovascular treatment. Methods— We conducted a multinational cross-sectional web-based study comprising of 607 clinicians and interventionalists from 38 countries who are directly involved in acute stroke care. Participants were randomly allocated to 10 from a pool of 22 acute stroke case scenarios. Each case was classified as either Class I, Class II, or unknown evidence according to the current guidelines. We used logistic regression analysis applying weight of evidence approach. Main outcome measures were multilevel factors associated with EVT, adherence to current EVT guidelines, and practice gaps between current and ideal practice settings. Results— Of the 1330 invited participants, 607 (45.6%) participants completed the study (53.7% neurologists, 28.5% neurointerventional radiologists, 17.8% other clinicians). The weighed evidence approach revealed that National Institutes of Health Stroke Scale (34.9%), level of evidence (30.2%), ASPECTS (Alberta Stroke Program Early CT Score) or ischemic core volume (22.4%), patient’s age (21.6%), and clinicians’ experience in EVT use (19.3%) are the most important factors for EVT decision. Of 2208 responses that met Class I evidence for EVT, 1917 (86.8%) were in favor of EVT. In case scenarios with no available guidelines, 1070 of 1380 (77.5%) responses favored EVT. Comparison between current and ideal practice settings revealed a small practice gap (941 of 6070 responses, 15.5%). Conclusions— In this large multinational survey, stroke severity, guideline-based level of evidence, baseline brain imaging, patients’ age and physicians’ experience were the most relevant factors for EVT decision-making. The high agreement between responses and Class I guideline recommendations and high EVT use even when guidelines were not available reflect the real-world acceptance of EVT as standard of care in patients with disabling acute ischemic stroke.